Document is current
Any future updates will be listed below
-
Authors
Riccardi, Veronica
Viscomi, Carlo Fiore
Sandri, Marco
D’Alessandro, Angelo
Dzieciatkowska, Monika
Stephenson, Daniel
Federti, Enrica
Hermann, Andreas
Salviati, Leonardo
Siciliano, Angela
Andolfo, Immacolata
Alper, Seth L.
Ceolan, Jacopo
Iolascon, Achille
Vattemi, Gaetano
Danek, Adrian
Walker, Ruth H.
Mensch, Alexander
Otto, Markus
Deschauer, Marcus
Armbrust, Moritz
Beninca’,, Cristiane
Salari, Valentina
Fabene, Paolo
Peikert, Kevin
De Franceschi, Lucia
-
Funding
Funding for this research was provided by:
Hermann und Lilly Schilling-Stiftung für Medizinische Forschung
Advocacy for Neuroacanthocytosis Patients
U.S. Department of Veterans Affairs (CX0002342)
Rostock Academy of Science
FUR-UNIVR
- License Information
-
More Information
Article History
Received: 18 February 2025
Accepted: 3 April 2025
First Online: 24 April 2025
Declarations
:
: The Institutional Animal Experimental Committee of University of Verona (CIRSAL) and Italian Ministry of health approved the experimental protocol (56DC9.12) following European directive 2010/63/EU and the federation for laboratory animal science associations guidelines and recommendations. The muscle biopsies of patients with VPS13A disease were obtained for routine diagnostic reasons (P1 and P2) and postmortem (P3). Retrospective scientific use of remaining biopsy specimens/muscle samples was approved by the institutional review boards of the University Medical Center Rostock (A 2022-0058) and University Medicine Halle (2021 − 101).
: Not applicable.
: The authors declare no competing interests.
